This report provides a systematic review of the benefits of radiotracers, specifically 18F-FDG-PET/CT, in detecting bone metastases in pediatric patients with renal carcinoma. The study emphasizes the importance of early detection for optimal treatment and accurate staging. The methodology includes a retrospective analysis of 60 patients, evaluating the correlation between 18F-FDG accumulation and survival rates. The results highlight the diagnostic value of 18F-FDG-PET/CT, demonstrating its ability to provide new information in a significant percentage of cases and its potential to inform therapeutic strategies. The report also discusses the relationship between SUVmax values, tumor grade, and mortality rates. The conclusion reinforces the utility of 18F-FDG-PET/CT as a decision-making tool in the management of renal carcinoma, underscoring the need for automated and two-phase CT-angiography for optimal results. The study utilizes skeletal scintigraphy to determine the early detection of the skeletal metastasis. The report discusses the use of radiotracers and its benefits in diagnosing bone metastases in renal carcinoma cases.
![[object Object]](/_next/static/media/star-bottom.7253800d.svg)
